Microtextured pHEMA Artificial Cornea for Tissue Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The current methods for treating corneal blindness are limited by the scarcity of donor tissue, high rejection rates, and functional defects in transplanted corneas, leading to inefficient and inaccessible corneal transplantation solutions, especially with the rising demand due to a growing geriatric population and increasing eye diseases.
Innovation Solution
A microtextured artificial cornea made of Poly(2-hydroxyethyl methacrylate) (pHEMA) hydrogel that is biocompatible, promoting rapid proliferation of corneal epithelial cells and adhesion of corneal fibroblasts, reducing the risk of infection and inflammation, and eliminating the need for donor tissue by mimicking the mechanical properties of human tissue with a soft but durable design.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If stiff materials like PMMA are used for artificial cornea, then structural strength is improved, but tissue extrusion and inflammation risks increase
Solution Approach 1:
The patent changes the mechanical parameter (Young's Modulus) of the artificial cornea material from the gigapascal range (PMMA: 2-3 GPa) to the megapascal range (pHEMA: 1-10 MPa), making it softer and more compliant with native corneal tissue. This parameter change reduces mechanical mismatch, thereby decreasing risks of tissue extrusion and inflammation while maintaining sufficient structural strength for permanent wear
2Ease of manufacture
If smooth surface artificial cornea is used, then manufacturing simplicity is improved, but integration with native tissue is reduced
Solution Approach 1:
The patent applies microtexturing only to the surface layer of the pHEMA hydrogel, creating micropores (5-20 μm) and/or microlines (1-10 μm wide) that enhance cell adhesion and tissue integration. The bulk material retains its uniform soft hydrogel properties, thus achieving improved tissue integration while maintaining the biocompatibility and mechanical properties of the base material
3Reliability
If donor tissue is used for corneal transplantation, then biocompatibility is improved, but availability and accessibility are reduced
Solution Approach 1:
The patent creates an artificial cornea that copies the mechanical properties (softness, flexibility) and biological functionality of natural corneal tissue using pHEMA hydrogel. The microtextured surface mimics the natural corneal epithelium structure, enabling cell adhesion and tissue regeneration without requiring actual donor tissue, thereby making the treatment widely available and accessible
Data Source
AI summary
An artificial cornea and an associated manufacturing method are disclosed. The artificial cornea has two sides, each of which has an associated microstructure. In an embodiment, microlines can be provided on an anterior side, and a posterior side can have micropores. Both the geometry of the microstructures and their dimensions can be customized for an individual patient. The geometry of the artificial cornea itself and its dimensions can also be customized as such. In addition, the lifetime of the artificial cornea can be significantly enhanced by adding co-polymer(s) into the hydrogel to strengthen its mechanical properties. Patient recovery can be aided by adding peptides into the artificial cornea surfaces to improve cell growth post-operation.